- Home
- / Cadrenal Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cadrenal Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$15.5
2024-10-29
Market Capitalization
$18.4 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| Cost of goods sold | 220.1K | |||
| General and administrative expense | 2.3M | 3.5M | 6.8M | |
| Operating expense total | 2.7M | 11.0M | ||
| Depreciation and amortization | 1.3K | |||
| EBIT | (2.7M) | (7.6M) | (11.0M) | |
| Investment income | 249.1K | 309.3K | ||
| Interest income | 249.1K | 309.3K | ||
| Interest expense | 40.2K | |||
| Pre tax profit | (6.7M) | (8.4M) | 10.7M | (13.2M) |
| Net Income | (6.7M) | (8.4M) | (10.7M) | |
| EPS | (0.8) | (8.7) | (6.6) |